Company intelligence / Profile preview
Araris Biotech AG
Au / Villigen*, Zurich/Aargau*, Switzerlandararisbiotech.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Araris’ ADC candidates have demonstrated improved efficacy and tolerability in preclinical studies compared to existing ADCs. The company’s proprietary technology enables site-specific, one-step conjugation of payloads to off-the-shelf antibodies without prior engineering, resulting in stable, homogeneous ADCs with a favorable therapeutic index. No clinical results have been published as of the acquisition by Taiho Pharmaceutical[5][9].
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugates (ADCs)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Taiho Pharmaceutical Co., Ltd.Chugai Pharmaceutical Co., Ltd.[1][5][8]
Beyond the preview
Go deeper on Araris Biotech AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Araris Biotech AG.